Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg
Study Details
Study Description
Brief Summary
The objective of this study was to investigate the bioequivalence of Mylan's ondansetron 24 mg tablets to GSK's Zofran® 24 mg tablets following a single, oral 24 mg (1 x 24 mg) dose administered under fasting conditions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 Ondansetron Tablets 24 mg |
Drug: Ondansetron Tablets 24 mg
24mg, single dose fasting
|
| Active Comparator: 2 Zofran® Tablets 24 mg |
Drug: Zofran® Tablets 24 mg
24mg, single dose fasting
|
Outcome Measures
Primary Outcome Measures
- Bioequivalence [within 30 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age: 18 years and older.
-
Sex: Male or non-pregnant, non-lactating female
-
Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study.
-
Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. Acceptable forms of contraception include the following:
-
intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
-
barrier methods containing or used in conjunction with a spermicidal agent, or
-
postmenopausal accompanied with a documented postmenopausal course of at least one year, or
-
surgical sterility (tubal ligation, oophorectomy or hysterectomy).
-
During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive method. This advice should be documented in the informed consent form.
-
Weight: At least 60 kg (132 lbs) for males and 48 kg (106 lbs) for females and all subjects within 15% of their Ideal Body Weight (IBW), as referenced by the Table of Desirable Weights of Adults Metropolitan Life Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
-
All subjects should be judged to be normal and healthy during a prestudy medical evaluation (physical examination, laboratory evaluation, hepatitis B and hepatitis C tests, HIV test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiate screen, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.
Exclusion Criteria:
-
Institutionalized subjects will not be used.
-
Social Habits:
-
Use of any tobacco products within 1 year of the start of the study.
-
Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
-
Ingestion of any vitamins or herbal products within the 48 hours prior to the initial dose of the study medication.
-
Any recent, significant change in dietary or exercise habits.
-
Positive test for any drug included in the urine drug screen.
-
Medications:
-
Use of any medication within the 14 days prior to the initial dose of study medication. Hormonal contraceptives and hormonal replacement therapy should NOT be used within 3 months of initial study medication.
-
Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
-
Use of any psychotropic agents/drugs within 1 year of the start of the study.
-
Diseases:
-
History of any significant chronic disease and/or hepatitis.
-
History of drug and/or alcohol abuse.
-
History of ulceration or gastritis considered to be clinically significant.
-
Acute illness at the time of either the pre-study medical evaluation or dosing.
-
Positive HIV, Hepatitis B or Hepatitis C test.
-
Abnormal and clinically significant laboratory test results:
-
Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
-
Abnormal and clinically relevant ECG tracing.
-
Donation or loss of a significant volume of blood or plasma (> 424 mL) within 28 days prior to the initial dose of study medication.
-
Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
-
Allergy or hypersensitivity to ondansetron or other selective serotonin receptor antagonist products.
-
History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
-
Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gateway Medical Research, Inc. | St. Charles | Missouri | United States | 63301 |
Sponsors and Collaborators
- Mylan Pharmaceuticals Inc
Investigators
- Principal Investigator: Walter A Parham, M.D., Cetero Research, San Antonio
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- Mylan Pharmaceuticals Inc. - Clinical Trial Results
- Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use
- Recalls, Market Withdrawals and Safety Alerts
Publications
None provided.- ONDA-0313